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IMPROVED AIRWAY 
HEALING AFTER LUNG 
TRANSPLANTATION 
An ana lys i s  o f  348 
bronch ia l  anastomoses  
We evaluated various clinical factors to identify predictors of airway 
complication after lung transplantation. Two hundred twenty-nine consec- 
utive single (n = 110) and bilateral (n = 119) lung transplants were done 
between September 1988 and August 1994. These 348 bronchial anastomo- 
ses were retrospectively analyzed. Airway complication that necessitated 
clinical intervention affected 33 anastomoses (9.5%) in 29 patients (12.8%). 
Satisfactory healing was achieved in 22 of these patients by conservative 
therapy such as one or a combination of dilation, stent, and laser. There were 
five deaths (2.2%) attributable to airway complications. One patient had an 
early postoperative d ath unrelated to airway complication and one patient has 
a recalcitrant bronchus intermedius tricture. Complication occurred more 
often in single-lung than in bilateral lung transplants (16/110, 14.4%, versus 
17/238, 7.1%; p < 0.05). The use of a mattress uture (21/153, 13.7%) was 
associated with more frequent complications than was simple interrupted 
suture (8/122, 6.6%) or figure-of-eight suture (4/73, 5.5%) (p < 0.05). For
patients in whom airway complications subsequently developed, the duration 
of postoperative mechanical ventilation was greater than that for those in 
whom an airway complication did not develop. The prevalence of airway 
complications as our program evolved was evaluated by separating the 229 
transplants into three groups: phase I, the first 77 transplants; phase II, the 
next 76 transplants; and phase HI, the most recent 76 transplants. The airway 
complication rate per anastomosis was significantly lower in phase III (5/126, 
4.0%) than in phase I (12/110, 10.9%; p < 0.05) and phase II (16/112, 14.3%; 
p < 0.01). The majority of airway complications are successfully treated and 
rarely fatal. The recent reduction in prevalence of airway complications i
likely a result of better maintenance immunosuppression and rejection sur- 
veillance. (J THORAC CARDIOVASC SURG 1995;110:1424-33) 
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gical technique, postoperative care, and immuno- 
suppression have reduced the prevalence of air- 
way complications. Experienced centers have 
recently reported the prevalence of airway com- 
plications to be in the range of 7% to 14%. 2, 3 In 
our center airway complications represent an in- 
frequent source of mortality. 4 The opt imum tech- 
niques of bronchial anastomosis and of periopera- 
tive and postoperative treatment of transplant 
recipients remain controversial and vary from one 
center to another. This retrospective r view of our 
experience was conducted to evaluate various 
clinical factors and identify those that might be 
associated with the development of bronchial 
anastomotic omplications in a group of single 
(SLT) and bilateral sequential (BLT) lung trans- 
plant recipients. 
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Patients and methods 
Between September 1988 and August 1994, 229 SLTs 
(n = 110) and BLTs (n = 119) were done in 226 patients 
at Barnes Hospital. These 348 anastomoses were retro- 
spectively reviewed and evaluated in December 1994 with 
a minimum follow-up of 120 days. En bloc double-lung 
transplants (n = 8) were not included in this study. 
Donor lungs were harvested by the technique we have 
previously described. 5 All donors were pretreated with 
systemic heparin and the pulmonary artei~¢ bed was 
flushed with modified Euro-Collins solution after prosta- 
glandin E 1 (500 t~g) administration directly into the 
pulmonary artery. 
All transplants were done with the use of previously 
described techniques. 6, 7 The donor bronchus was short- 
ened to two rings proximal to the upper lobe takeoff. In 
our most recent 217 cases anastomoses were conducted in 
the following sequence: bronchus, pulmonary artery, left 
atrium. In the first 12 SLTs in our experience, the 
bronchial anastomosis was done last. The technique used 
for bronchial anastomosis has evolved with time. Until 
September 1991, an end-to-end anastomosis with simple 
interrupted 4-0 Vicryl polyglactin 910 sutures (Ethicon, 
Inc., Somerville, N.J.) was done in most cases. We then 
adopted a telescoping technique in most cases whenever 
the difference in bronchial size between the donor and the 
recipient was significant (see latter part of Results sec- 
tion). The anastomosis was constructed with 4-0 Prolene 
polypropylene (Ethicon) or polydioxanone (PDS, Ethi- 
con) sutures as described by Grilfith and associates 3 or 
with a figure-of-eight technique as described by Calhoon 
and colleagues. 7 We continued to use end-to-end anasto- 
moses with simple interrupted or figure-of-eight sutures 
when donor and recipient bronchi were of an equal size 
and for a small-caliber left bronchial anastomosis. Direct 
bronchial artery revascularization was not used. Some 
form of bronchial anastomotic coverage was used in all 
but four anastomoses. Early in our experience a pedicled 
flap of omentum was used routinely. Pericardial fat was 
later used in a small number of cases but the majority of 
anastomoses were covered with donor and recipient peri- 
bronchial fat and nodal tissue. Patients received methyl- 
prednisolone 500 to 1000 mg intravenously at the time of 
reperfusion. 
Standard immunosuppression consisted of azathioprine 
(2 mg/kg), cyclosporine, steroid, and antilymphocyte anti- 
body. Cyclosporine was given as a continuous infusion (3 
to 6 mg/hr) in the early postoperative p riod, followed by 
enteral administration when tolerated. The dose was 
adjusted to obtain a blood level in the high therapeutic to 
slightly supratherapeutic range. Until 1991 routine ther- 
apy with steroids was withheld during the early postoper- 
ative period. Subsequently methylprednisolone 0.5mg/kg 
per day intravenously was administered for 3 days, fol- 
lowed by oral prednisone 0.5 mg/kg per day. Induction 
cytolytic therapy was used in most patients. The_first six 
patients received OKT3. Toxicity of this agent prompted 
routine use of  Minnesota antilymphocyte globulin (15 
mg/kg per day intravenously) until July 1992 when that 
agent was no longer available. After a 6-month interval 
when no cyt~lytic therapy was used for induction, ATGAM 
lymphocyte immunoglobulin/antithymocyte globulin (Up- 
john Co., Kalamazoo, Mich.) 15 mg/kg per day intrave- 
nously was used routinely. 
Flexible fiberoptic bronchoscopy was frequently used to 
monitor donor airway viability and integrity of the bron- 
chial anastomosis. Patients routinely underwent initial 
bronchoscopic evaluation before they were taken from the 
operating room and again immediately before extubation. 
Routine surveillance bronchoscopies with bronchoalveo- 
lar lavage and transbronchial lung biopsies were done at 2 
to 3 weeks and 2, 3, 6, and 12 months, and annually 
thereafter. Bronchoscopy was done on other occasions 
dictated by clinical parameters such as dyspnea, hypox- 
emia, decline in pulmonary function test result, radio- 
graphic infiltrate, or unexplained fever. 
For purposes of this review, an airway complication was 
defined as a finding of significant dehiscence that neces- 
sitated extended chest tube drainage or other surgical 
intervention or a finding of stenosis or malacia that 
necessitated dilation, debridement, laser therapy, or stent 
placement. Partial dehiscence, mucosal necrosis, or slough 
detected by bronchoscopy was not considered an airway 
complication when satisfactory healing occurred without 
further intervention. 
Various clinical factors were evaluated to identify pre- 
dictors of airway complication. Factors evaluated were 
recipient factors (age, sex, diagnosis, previous preopera- 
tive steroid history, current preoperative steroid use), 
donor factors (age, sex, arterial oxygen tension [Pao2] at 
fraction of inspired oxygen [Fio2] 100% and 5 cm H20 
positive end-expiratory pressure, ischemic time), opera- 
tive factors (type of transplant, side of transplant, require- 
ment for cardiopulmonary b pass, type of bronchial anas- 
tomosis, suture technique, suture material, type of 
wrapping), and postoperative factors (Pao 2 at Fioa 100%, 
mean systemic pressure, mean arterial pressure, cardiac 
output, peak airway pressure: all measured on arrival in 
the intensive care unit). Other postoperative factors in- 
cluded used of continuous intravenous prostaglandin E 1 
infusion during the first 24 postoperative hours, percent- 
age of allograft perfusion measured by quantitative ven- 
tilation-perfusion nuclear scintigraphy within the first 12 
postoperative hours, duration of mechanical ventilation, 
early maintenance steroid use, number of 3-day bolus 
methylprednisolone course given as therapy for suspected 
acute rejection within the first 30 days, total dose of bolus 
methylprednisolone given within the first 30 days, the first 
day of bolus methylprednisolone given, type of induction 
cytolytic therapy, transbronchial biopsy-proven A2 or 
greater acute rejection within the first 30 days, cytomeg- 
alovirus status, and biopsy-proven cytomegalovirus pneu- 
monia within the first 90 days. 
The prevalence of airway complications during different 
stages of our program was evaluated by separating the 229 
transplants into three groups: phase I, the first 77 trans- 
plants; phase II, the next 76 transplants; and phase III, the 
most recent 76 transplants. All parameters noted previ- 
ously were evaluated among the three phases. 
Predictors of airway complications were analyzed by 
multivariate analysis. Significance was sought among three 
phases with use of a X 2 test for nonparametric data and 
analysis of variance and the Tukey honest significant 
difference multiple comparisons procedure for parametric 
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Table I. Recipient preoperative factors 
Group I: no Group H: 
complication complication p 
Factors (n = 315) (n = 33) Value 
Age (yr) 42.8 _+ 11.7 44.6 _+ 12.1 NS 
Sex NS 
Male 157 (49.8) 15 (45.5) 
Female 158 (50.2) 18 (54.5) 
Diagnosis NS 
Obstructive 176 (55.9) 19 (57.6) 
Restrictive 27 (8.6) 4 (12.1) 
Septic 72 (22.9) 6 (18.2) 
PVD 40 (12.7) 4 (12.1) 
Remote steroid history NS 
Yes 221 (70.2) 23 (69.7) 
No 94 (29.8) 10 (30.3) 
Preop. steroid use NS 
Yes 84 (26.7) 12 (36.4) 
No 231 (73.3) 21 (63.6) 
Values in parentheses indicate percentage. NS, Not significant; PVD, 
primary pulmonary hypertension, Eisenmenger's syndrome. 
Table II. Donor factors 
Group I: no Group II: 
complication complication p 
Factors (n = 315) (n = 33) Value 
Age (yr) 27.8 -+ 10.9 24.7 _+ 11.8 NS 
Sex NS 
Male 221 (70.2) 27 (81.8) 
Female 94 (29.8) 6 (18.2) 
Pao2 (ram Hg) 470 _+ 80 494 _+ 63 NS 
Ischemic time (rain) 314 +_ 93 291 _+ 102 NS 
Values in parentheses indicate percentage. Pao2 was measured with Fio 2 
100%, 5 cm H20 positive end-expiratory pressure. NS, Not significant. 
data. Data are expressed as mean plus or minus 1 standard 
deviation. Statistical significance was accepted at the 95% 
confidence l vel, p < 0.05. 
Results 
Airway complication. Significant dehiscence af- 
fected 15 anastomoses in 12 patients 15.7 _+ 10.7 
days (4 to 38 days) after transplantation. Five pa- 
tients, including two patients who underwent re- 
transplantation, died of this complication. In an- 
other five patients, chest tube or mediastinal tube 
placement, or both, to achieve complete reexpan- 
sion of the lung permitted satisfactory closure of the 
leak. Although a stricture ultimately developed in 
one patient, it was successfully managed by subse- 
quent dilation. In one patient, a silicone-rubber 
stent was placed 26 days after transplantation with a 
satisfactory result. In one patient, sudden death of 
unknown cause occurred 3 days after chest tube 
placement. 
Significant stenosis occurred in 18 anastomoses 
among 17 patients 105.2 _+ 86.7 days (24 to 385 days) 
after transplantation. All but one case were success- 
fully managed by conservative therapy such as one 
or a combination of dilation (17 patients), stent (11 
patients), and laser (4 patients). One bilateral ung 
recipient had complete obstruction of the bronchus 
intermedius, which could not be adequately treated. 
In summary, airway complications that necessi- 
tated clinical intervention occurred in 29 patients 
(12.8%) and 33 anastomoses (9.5%). Conservative 
therapy resulted in excellent improvement in 22 
patients. There were five deaths (2.2%) attributable 
to airway complications. 
Evaluation of clinical factors. Various clinical 
factors were evaluated by comparing the cases of the 
315 anastomoses that healed without complication 
(group I) with the cases of the 33 anastomoses that 
necessitated clinical intervention (group II). 
Recipient factors (Table I) and donor factors 
(Table II) were not significantly different between 
the two groups. 
Data from analysis of operative factors are shown 
in Table III. Anastomotic omplications occurred 
more often in SLT than in BLT (16/110, 14.4%, 
versus 17/238, 7.1%; p < 0.05). Mattress suture 
(21/153, 13.7%) was associated with more frequent 
complications than was simple interrupted suture 
(8/122, 6.0%) or figure-of-eight suture (4/73, 5.5%) 
(p < 0.05). No correlation was found between 
transplant side, use of cardiopulmonary bypass, 
anastomosis type (end-to-end versus telescope), su- 
ture material, or type of wrapping and the subse- 
quent development of an airway complication. 
Postoperative factors in the intensive care unit 
(ICU) are summarized in Table IV. Patients in 
whom airway complications subsequently developed 
had required longer postoperative mechanical ven- 
tilation than those without airway complications 
(12.9 + 18.4 days versus 5.5 _+ 20.5 days, p < 0.01). 
Among 289 anastomoses subjected to mechanical 
ventilation for less than 7 days, 22 (7.6%) complica- 
tions were observed. In contrast, among 59 anasto- 
moses ubjected to mechanical ventilation for longer 
than 7 days, 11 (18.6%) complications were noted 
(p < 0.01). Pao2, mean arterial pressure, mean 
pulmonary artery pressure, cardiac output, and peak 
airway pressure were not significantly different be- 
tween the two groups. Use of prostaglandin E l and 
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the percentage of pulmonary perfusion to the anas- 
tomosis side did not correlate with the subsequent 
development of airway complications. 
Other postoperative factors regarding immuno- 
suppression, rejection, and cytomegalovirus infec- 
tion are shown in Table V. There was no significant 
difference between the two groups with respect to 
any of these factors. 
Prevalence of airway complications with evolu- 
tion of transplant program. The prevalence of 
airway complications in different phases of our 
series is summarized in Table VI. The airway 
complication rate was significantly reduced to 
4.0% in phase III from 10.9% in phase I and 
14.3% in phase II. 
We speculated that this recent decrease in airway 
complications might be a result of various changes 
in technical and clinical management practices over 
time. We therefore reevaluated all the clinical fac- 
tors listed in Tables I through V. Factors that 
changed significantly among the three phases are 
shown in Table VII. All other factors were not 
significantly different among the three phases. 
Significant technical change occurred between 
phase I and phase II. In phase I, the standard 
technique was an end-to-end anastomosis with sim- 
ple interrupted 4-0 Vicryl polyglactin 910 sutures 
followed by bronchial omentopexy. In phase II, a 
telescoping anastomosis with modified mattress 4-0 
PDS polyd~oxanone sutures followed by wrapping 
with peribronchial nodal tissue was commonly used. 
No significant technical change was made between 
phase II artd phase III except that omentopexy was 
completely abandoned in phase III. Preoperative 
steroid use and postoperative prostaglandin E 1 in- 
fusion were significantly increased in phase II com- 
pared with their use in phase I. However, there was 
no difference between phase II and phase III. 
Postoperative immunosuppression and rejection 
monitoring were changed significantly between 
phase I! and phase IlI. Low-dose corticosteroid 
administration from day 1 along with induction 
cytolytic therapy with antithymocyte globulin was 
routinely used in phase III. Rejection therapy by 
bolus injection of methylprednisolone was mainly 
based on histologic (transbronchial ung biopsy) 
evidence rather than empiric clinical diagnosis (such 
as fever, cough, shortness of breath, decrease of 
Pao2) in phase III. As a result, course of methyl- 
prednisolone and total dose of methylprednisolone 
given withih 30 days were significantly decreased 
Table IlL Operative factors 
Airway 
complication p 
Factors rate Value 
Operation type < 0.05 
SLT 16/110 (14.4) 
BLT 17/238 (7.1) 
Side NS 
Right 17/174 (9.8) 
Left 16/174 (9.2) 
CPB NS 
Yes 12/102 (11.8) 
No 21/246 (8.5) 
Anastomosis type NS 
End-to-end 11/158 (7.0) 
Telescope 22/190 (11.6) 
Donor into recipient 13/102 (12.8) 
Recipient into donor 9/88 (10.2) 
Suture technique < 0.05 
Simple 8/122 (6.6) 
Figure-of-eight 4/73 (5.5) 
Mattress 21/153 (13.7) 
Suture material NS 
PDS polydioxanone 20/243 (8.2) 
Vicryl polyglactin 910 10/93 (10.8) 
Prolene polypropylene 3/12 (25.0) 
Wrapping NS 
Omentum 10/t12 (8.9) 
Peribronchial tissue 17/194 (8.8) 
Pericardial fat 5/36 (13.9) 
Intercostal muscle 0/2 (0.0) 
None 1/4 (25.0) 
Values in parentheses indicate percentage. NS, Not significant; CPB, 
cardiopulmonary bypass. 
Table IV. Postoperative factors (ICU) 
Group I: no Group IL" 
complication complication p 
Factors (n = 315) (n = 33) Value 
PaO2 (ram Hg) 346 + 153 317 _+ 152 NS 
BP (mm Hg) 79.6 + 11.0 83.9 -+ 10.6 NS 
PAP (mm Hg) 23.3 -+ 6.4 24.5 _+ 5.1 NS 
CO (L/rain) 4.7 + 1.4 4.7 _ 1.0 NS 
PGE1 NS 
Yes 214 (67.9) 25 (75.8) 
No 101 (32.1) 8 (24.2) 
Perfusion scan (to 58.0 -+ 20.5 64.9 ± 17.5 NS 
anastomosis) (%) 
Peak airway pressure 31.1 z 5.7 31.2 ± 6.3 NS 
(cm H20 ) 
Mechanical ventilation 5.5 -+ 9.9 12.9 + 18.4 <0.01 
(days) 
Values in parentheses indicate percentage. Pao2, arterial pressure, pulmo- 
nary artery pressure, cardiac output, and peak airway pressure were 
measured 1 hour after the patient was admitted to ICU. Pao2, Arterial 
oxygen tension with Fio 2 100%; NS, not significant; BP, mean arterial 
pressure; PAP, mean pulmonary artery pressure; CO, cardiac output; 
PGE l, prostaglandin El.
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Table Vo Postoperative factors (immunosuppression, 
rejection, cytomegalovirus) 
Group 1." no Group II." 
complication complication p 
Factors (n = 315) (n = 33) Value 
Postop. steroid use NS 
From day 1 173 (54.9) 19 (57.6) 
From day 4-7 133 (42.2) 12 (36.4) 
From day 21 9 (2.9) 2 (6.1) 
Courses of MPD <30 days 1.9 +- 1.0 1.9 -+ 1.1 NS 
MPD given <30 days (gm) 2.4 _+ 1.3 2.6 +_ 1.5 NS 
First bolus MPD (day) 5.7 _+ 4.1 4.6 + 2.8 NS 
Cytolytic therapy NS 
ALG 160 (50.8) 18 (54.5) 
ATG 128 (40.6) 6 (18.2) 
oIcr3 5 (1.6) 1 (3.0) 
None 22 (7.0) 8 (24.2) 
A2 rejection or greater NS 
<30 days* 
Yes 105 (34.7) 6 (22.2) 
No 197 (65.2) 21 (77.8) 
Recipient/donor CMV status NS 
N/N 62 (19.7) 5 (15.2) 
P/N 68 (21.6) 8 (24.2) 
N/P 91 (28.9) 9 (27.3) 
P/P 94 (29.8) 11 (33.3) 
CMV pneumonia <90 days? NS 
Yes 108 (37.5) 6 (26.1) 
No 180 (62.5) 17 (73.9) 
Values in parentheses indicate percentage. NS, Not significant; MPD, 
methylprednisolone (Upjohn); ALG, antilymphocyte globulin; ATG, anti- 
thymocyte globulin (Upjohn); OKT3, monoclonal antibody to the CD3 
receptor on lymphocytes (Ortho Pharmaceutical Corp., Raritan, N.J.); 
CMV,, cytomegalovirus; N, negative; P, positive. 
*Data obtained from the patients who survived more than 30 days. 
"~Data obtained from the patients who survived more than 90 days. 
and the first bolus methylprednisolone dose was 
significantly delayed in phase III compared with that 
in phases I and II. Biopsy-proven A2 or greater 
rejection within the first 30 days was documented in 
more recipients in phase III than in phases I and II. 
This is because of the increase in biopsy procedures 
in phase III. The number of early transbronchial 
lung biopsies done was 67 in phase I, 104 in phase II, 
and 151 in phase III. The prevalence of A1 or 
greater rejection per biopsy procedure was un- 
changed among the three phases. 
Discussion 
Historically, poor bronchial healing was a major 
problem after lung transplantation. 1 Without recon- 
nection of the bronchial arterial circulation, airway 
viability is exclusively dependent on vascular supply 
by retrograde collateral flow from pulmonary to 
bronchial circulation. On the basis of favorable 
Table VI. Chronologic prevalence of airway 
complications 
Phase I Phase II Phase III 
Period 1988.5-1991.7 1991.8-1993.3 1993.4-1994.8 
No. of 77 76 76 
transplants 
Single/bilateral 42/35 40/36 28/48* 
No. of 110 112 126 
anastomoses 
Airway 12/110 (10.9) 16/112 (14.3) 5/126 (4.0)t 
complication 
Values in parentheses indicate percentage. 
*p < 0.05 (versus phase I). 
?p < 0.05 (versus phase I),p < 0.01 (versus phase II). 
results from a number of laboratory investiga- 
tions, s-1° routine use of bronchial anastomotic 
omentopexy and avoidance of high-dose periopera- 
tive corticosteroids were thought to be key strategies 
for the first successful series of human lung trans- 
plants. 11 However, recent studies have demon- 
strated that omentopexy is no longer essential and 
that modest early doses of postoperative corticoste- 
roids do not impair airway healing. 12-14 Alternative 
techniques uch as telescoping anastomosis 7 and 
direct bronchial revascularization ~5-*r have been re- 
ported with low rates of airway complication. 
The ideal techniques of bronchial anastomosis 
and perioperative and postoperative treatment of 
transplant recipients are controversial nd vary from 
one center to another. However, results appear 
similar even when different techniques are used. We 
have previously reported no difference in the prev- 
alence of bronchial anastomotic complications from 
a concurrent series of patients who underwent trans- 
plantation at Washington University and the Univer- 
sity of Toronto] 3Patients who underwent transplan- 
tation at the University of Toronto had mattressed 
anastomoses wrapped with local nodal tissue and 
received routine perioperative steroids. Patients 
who underwent transplantation at Washington Uni- 
versity had end-to-end anastomoses wrapped in a 
pedicled flap omentum and did not receive routine 
early perioperative corticosteroids. 
Having a large number of airway anastomoses for 
analysis, we were provided with an opportunity to 
review each of these factors in our own group of 
patients. The technique of bronchial anastomosis is 
undoubtedly important. Our experience did not 
show a significant difference in the airway complica- 
tion rate between end-to-end and telescoped anas- 
tomoses. It should also be noted that there was no 
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Table VII .  Chronologic change of clinical factors 
p Value 
Factors Phase I Phase H Phase Ill I vs. H I vs. III H vs. III 
Preop. steroid use <0.001 <0.001 NS 
Yes 6 (7.8) 22 (28.9) 32 (42.1) 
No 71 (92.2) 54 (71.1) 44 (57.9) 
Anastomosis type* <0.001 <0.001 NS 
End-to-end 92 (83.6) 25 (22.3) 41 (32.5) 
Telescope 18 (16.4) 87 (77.7) 85 (67.5) 
Suture technique* <0.001 <0.001 NS 
Simple 88 (80.0) 18 (16.1) 16 (12.7) 
Figure-of-eight 18 (16.4) 22 (19.6) 33 (26.2) 
Mattress 4 (3.6) 72 (64.3) 77 (61.1) 
Suture material* <0.001 <0.001 NS 
PDS polydioxanone 33 (30.0) 94 (83.9) 116 (92.1) 
Vicryl polyglactin 910 72 (65.5) 11 (9.8) 10 (7.9) 
Prolene polypropylene 5 (4.5) 7 (6.3) 0 (0.0) 
Wrapping * <0.001 <0.001 <0.001 
Omentum 98 (89.1) 14 (12.5) 0 (0.0) 
Peribronchial 0 (0.0) 77 (6.9) 117 (92.9) 
Pericardial fat 8 (7.3) 20 (17.9) 8 (6.3) 
Intercostal muscle 2 (1.8) 0 (0.0) 0 (0.0) 
None 2 (1.8) 1 (0.9) 1 (0.8) 
PGE 1 <0.001 <0.001 NS 
Yes 30 (39.0) 69 (90.8) 68 (89.5) 
No 47 (61.0) 7 (9.2) 8 (10.5) 
Postop. steroid use <0.001 <0,001 <0.001 
From day 1 3 (3.9) 48 (63.2) 68 (89.5) 
From day 4-7 63 (81,8) 28 (36.8) 8 (10.5) 
From day 21 11 (14,3) 0 (0.0) 0 (0.0) 
Courses of MPD (<30 days) 2.2 _+ 0.9 2.4 ± 0.9 1.5 + 0.9 NS <0,001 <0.001 
MPD given <30 days (gm) 2.7 _+ 1.1 2.9 ± 1.3 1.9 -+ 1.3 NS <0,005 <0.001 
First bolus MPD (day) 3.9 ± 2.1 4.3 ± 2.1 8.3 + 5.2 NS <0,001 <0.001 
Cytolytic therapy <0.001 <0.001 <0.001 
ALG 69 (89.6) 53 (69.7) 0 (0.0) 
ATG 0 (0.0) 9 (11.8) 74 (97.4) 
OKT3 6 (7.8) 0 (0.0) 0 (0.0) 
None 2 (2.6) 14 (18.4) 2 (2.6) 
A2 rejection or greater <30 days NS <0.001 <0.05 
Yes 15 (19.5) 19 (25.0) 33 (43.4) 
No 62 (80.5) 57 (75.0) 43 (56.6) 
Values in pareniheses indicate percentage. NS, Not significant; PGE 1, prostaglandin El; MPD, methylprednisolone; ALG, antilymphocyte globulin; ATG, 
antithymocyte g!obulin; OKT3, monoclonal antibody tothe CD3 receptor on lymphocytes. 
*Data were obtained per anastomosis. All the other data were obtained per transplant. 
difference whether the donor or recipient bronchus 
was intussuscepted. However, in this series the 
modified mattress suture used for a telescoping 
anastomosis was associated with a significantly 
greater rate of complications (13.7%). Griffith and 
associated 3 has reported a similar complication rate 
(12%) with use of this technique. When figure-of- 
eight suture was used for a telescoping anastomosis, 
the prevalence of airway complication was only 
3.1%. A mgdified mattress suture technique more 
readily achieves the desired intussusception and it 
avoids the potential creation of an obstructing 
flange of invaginated cartilage (Fig. 1). However, no 
strength is given between the overlapped cartilages. 
On the other hand, figure-of-eight suture gives firm 
strength between the overlapped cartilages although 
it is somewhat more difficult to achieve complete 
telescoping. Our current policy is as follows. When 
the bronchial size is equivalent, we use end-to-end 
anastomosis either by simple interrupted or figure- 
of-eight sutures. For a small left bronchial anasto- 
mosis, we recommend simple interrupted suture. 
When the discrepancy in bronchial size is obvious, 
we use a telescoping technique either by figure-of- 
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Fig. 1. A, Modified mattress suture. This technique holds 
rings of smaller airway to mucosal surface of larger airway 
to avoid potential for obstruction of flange of invaginated 
cartilage. However, no strength is given between two 
overlapped cartilages. B, Figure-of-eight suture. Firm 
strength is given between two overlapped cartilages al- 
though it is more difficult o achieve telescoping. 
eight sutures when it is easy to achieve an intussus- 
ception or by a modified mattress uture technique 
when it is somewhat more difficult to achieve a 
telescoped result. 
There was no difference in the airway complica- 
tion rate among the types of bronchial wrapping. A 
prospective randomized study recently reported by 
Khaghani and colleagues 18has demonstrated that 
the prevalence of bronchial anastomotic complica- 
tions after SLT is not affected by wrapping the 
anastomosis with either omentum or an internal 
mammary artery pedicle. Our current standard is 
wrapping the anastomosis with peribronchial nodal 
tissue because this is easy to achieve and eliminates 
any direct contact between the bronchial and pul- 
monary artery anastomosis. 
It is interesting that none of the preoperative 
recipient factors evaluated was a predictor of airway 
complication. Although high-dose preoperative cor- 
ticosteroid therapy may compromise bronchial heal- 
ing, in our experience modest doses of preoperative 
prednisone do not affect airway integrity. Of note 
was that preoperative steroid use did not compro- 
mise airway integrity. This is the same conclusion 
that the San Antonio group has previously re- 
ported] Postoperative low-dose corticosteroid ad- 
ministration also did not increase airway complica- 
tions, which confirms previous reports from the San 
Antonio 7 and Hannover 12 groups. 
It is interesting that airway complications were 
more commonly observed in SLT recipients. With 
two bronchial anastomoses, BLT has a twofold risk 
of airway complication compared with SLT. Fur- 
thermore, the transplanted lung receives more pul- 
monary artery perfusion than the native lung in 
SLT, whereas both lungs are equally perfused in 
BLT. Yet we have previously reported that patients 
receiving SLT because of pulmonary fibrosis and 
primary pulmonary hypertension have a longer re- 
quirement for mechanical ventilation as a result of 
allograft dysfunction. 19This may compromise collat- 
eral bronchial flow in these allografts in comparison 
with that in bilateral grafts in which allograft dys- 
function is less commonly encountered. This may 
explain why SLT bronchial anastomoses were com- 
plicated more commonly than BLT anastomoses 
(14.4% versus 7.1%). The relationship between al- 
lograft dysfunction and airway complications i  fur- 
ther suggested by the fact that airway complications 
were much less commonly encountered in patients 
who received ventilator support for fewer than 
7 days (7.6%) in comparison with patients who re- 
ceived ventilator support longer than 7 days (18.6%). 
We do not believe that mechanical ventilation in 
and of itself predisposes to an increased prevalence 
of airway complications. Indeed, Yokomise and 
colleagues 2°have previously demonstrated that pos- 
itive end-expiratory pressure augments retrograde 
collateral bronchial mucosal flow. 
We acknowledge that this explanation for the 
differences in airway complications between SLT 
and BLT is speculative and impossible to confirm in 
this retrospective r view. A more practical explana- 
tion is also available. It is possible that the bias of 
our transplant program directors was to treat airway 
problems in SLT recipients more aggressively than 
the same problems in BLT recipients. Although this 
may be true, the fact remains that clinically signifi- 
cant airway complications occurred more frequently 
in SLT than BLT recipients. 
We observed a significant reduction in the airway 
complication rate to 4% during phase III. Major 
technical changes evolved between phase I and 
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phase IX but not between phase II and phase III as 
already described. Postoperative immunosuppres- 
sion and rejection monitoring changed significantly 
between phase II and phase III. In phase III, 
low-dose corticosteroid administration from day 1 
along with induction cytolytic therapy with antithy- 
mocyte globulin was routinely used and rejection 
therapy by bolus injection of methylprednisolone 
was mainly based on histologic rather than clinical 
diagnosis. These observations suggest hat the re- 
cent improvement in airway healing is likely a result 
of better maintenance immunosuppression and re- 
jection surveillance. Fujimura and associates 21have 
reported that lung allograft rejection is closely con- 
nected with wound healing of the bronchial anasto- 
mosis in canine lung transplantation. We think it is 
important o give timely but not excessive methyl- 
prednisolone for the treatment of acute rejection 
because pulmonary-to-bronchial collateral flow 
would be impaired by infection as well as by rejec- 
tion. 
The Harefield group is and Bordeaux group 16 
have both reported successful bronchial artery re- 
vascularization for en bloc double-lung transplanta- 
tion with tracheal anastomosis. Although we do not 
dispute the value of revascularization in that proce- 
dure, we remain unconvinced regarding its benefit in 
patients undergoing SLT and indeed BLT. Daly and 
McGregor 17 from the Mayo Clinic have reported a
small series of patients who underwent revascular- 
ization as part of a SLT procedure. We believe that 
this represents an additional technical challenge 
that is not necessary in the vast majority of patients 
and completely impractical in patients undergoing 
BLT. We await with interest the long-term follow-up 
results in these patients to determine whether such 
revascularization will have any impact on the ulti- 
mate development of bronchiolitis obliterans yn- 
drome, as has been proposed. 
Indeed, in the most recent 100 successive trans- 
plants conducted at our center, we have had only 
one death attributable to airway dehiscence. We 
believe thai: increasing experience, meticulous ur- 
gical technique, and rigorous postoperative care 
have significantly lessened the prevalence of airway 
complication after pulmonary transplantation. 
We acknowledge the assistance of Mary Ann Kelly in 
preparation of the manuscript and statistical advice from 
Richard B. Schuessler, PhD. 
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Discussion 
Dr. Walter Klepetko. (Vienna, Austria). This paper 
summarizes the current status of a long and outstanding 
surgical development, which has brought he problem of 
bronchial anastomosis down from being the most crucial 
one in lung transplantation to the reported remarkable 
figure of 4%. We all have to be indebted to the author's 
group and especially to Dr. Cooper and Dr. Patterson for 
their continuous work in the field. 
It is fascinating to observe how the importance of 
several factors that were believed to be so crucial in the 
early period has changed. Lung transplantation without 
omental wrapping was considered previously to be simply 
impossible. Nowadays this technique is hardly used any- 
more. In addition, the former assumption that early 
postoperative use of steroids could severely compromise 
bronchial healing has been changed into the beneficial 
concept of immediate postoperative application of ste- 
roids quite uniformly. 
This paper nicely demonstrates that healing of the 
airway depends on two major factors. Correct surgical 
technique is one of them. It is obviously less important 
which particular technique, end-to-end or telescope, is 
applied, as long as the surgeon has become experienced 
and familiar with it. It is also pointed out that not every 
technique should be applied in every anatomic situation. 
For instance, the telescoping technique in the presence of 
very small airways eems to be a poor option. On the other 
hand, adequate bronchial microcirculation plays a major 
role in prevention of bronchial problems and depends on 
a multitude of factors. This is shown nicely in this study by 
the fact that prolonged ventilation was associated with a 
higher prevalence of problems. Perioperative manage- 
ment, therefore, becomes crucial for microcirculation, and 
not the least important factor is efficient prevention, 
diagnosis, and treatment of rejection. 
In our own experience of about 120 lung transplanta- 
tions, the worst case of severe impairment of microcircu- 
lation occurred in a patient after BLT. At bronchoscopy, 
severe, almost complete, ischemia was present as far down 
as to the segmental bronchial orifices of the lower lobes. 
Despite the severity of the situation, we were able to treat 
the patient successfully with Y-shaped silicone stents 
extending into the upper lower lobe carina on the left and 
down the intermediate bronchus on the right side. After 6 
months one stent was lost and the patient underwent 
successful retransplantation. The patient is still alive 4 
years after that procedure. 
In light of these considerations, I would like to ask the 
authors three questions. First, could they give us more 
details about their postoperative r gimen of hepariniza- 
tion and prostaglandin E~ administration? Second, the 
authors mentioned in the manuscript that they are now 
accepting moderate doses of preoperative steroids. I 
would like to ask what they understand concerning the 
moderate dose and what the highest dose of steroids was 
that they ever accepted. Finally I would like to address a
question to Alec Patterson. Looking back at the more 
than 10-year period during which the technique of bron- 
chial anastomosis has significantly developed, what, in 
your opinion, was the initial benefit of omental wrapping? 
Was it simply a mechanical effect hat prevented catastro- 
phe or was it truly beneficial for the bronchial microcir- 
culation? 
Dr. Date. In the early several cases we used low-dose 
heparin systemically, but in the rest of the cases we used 
low-dose heparin, 5000 units every 12 hours, subcutane- 
ously, to prevent hrombotic omplications after the op- 
eration. We currently use prostaglandin E1 routinely, 
unless significant hypotension becomes a problem. 
Concerning preoperative use of steroids, we currently 
accept up to 20 mg prednisone daily. On occasion patients 
require acute augmentation f steroid therapy because of 
an exacerbation of the underlying disease. We still accept 
these patients, expecting that they are at increased risk of 
poor bronchial healing. 
Dr. Alee G. Patterson (St. Louis, Mo.). [ would like to 
initially congratulate Dr. Date for a great presentation 
and Dr. Klepetko for his kind remarks. For those of you 
who do not know, Dr. Klepetko has developed and now 
directs one of the most successful lung transplant pro- 
grams in Europe. 
I do not know precisely what the benefit of omental 
wrapping was in those early days, although I think it had 
two important benefits. First, it revascularized the isch- 
emic bronchus. Dr. Joel Cooper showed that nicely in a 
series of canine experiments years ago. I also think that it 
provided security and protection from mediastinal sepsis 
in those few patients who did have some bronchial dehis- 
cence. In those days the preservation that we used was 
terrible. We purposely made the donor lung atelectatic, 
heparinized the donor, removed the lung without he use 
of any flushing solution, kept it immersed in cold saline 
solution, and then placed it in the recipient while making 
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no attempt to keep it cold during the suturing. Given that, 
it is remarkable to me that any of those transplants 
worked, and it is no surprise that the donor pulmonary- 
to-bronchial collateral circulation was deficient in some of 
those cases. 
Dr. Hans.Joachim Sch/ifers (Hannover, Gelmany). The 
current prevalence of airway complications, in the range 
of 4%, certainly indicates that one of the major arguments 
of isolated lung transplantation versus heart-lung and 
domino transplantation is now an argument of the past. In 
a similar time frame, since 1988 up to the beginning of this 
year, we have in our lung transplant program done a total 
of 140 isolated lung transplants. We have observed airway 
complications in 13 of 210 anastomoses at risk, for a 
prevalence of 6.2%. Initially the prevalence was rather 
high, which prompted us to institute a protocol directed at 
improving bronchial microcirculation. This was indicated 
by experimental data, part of which was presented at the 
meeting of this Society 3 years ago. The patients were 
given steroids, heparin, and prostacyclin beginning in the 
immediate postoperative phase. In addition, as suggested 
by the San Antonio group, donor and recipient airways 
were kept short, which allowed us to omit omentopexy. 
End-to-end anastomosis with simple interrupted sutures 
has been the main approach, with telescoping of the 
bronchi used only for size discrepancy. 
Following this concept, we have observed a prevalence 
of airway complications of only 4%, that is, 8 complica- 
tions in the most recent 198 grafts at risk. We have, 
interestingly, observed a change in the type of complica- 
tions. Rather than having ischemia right at the site of the 
anastomosis, we have had problems limited to the lobar 
bronchi, especially the intermediate bronchus. If one 
excludes those isolated lobar complications, the preva- 
lence would only be 2.5%. 
In the past 2 years we have used parenchyma-sparing 
resection for the treatment of stenosis rather than stent- 
ing. The results have been excellent in the most recent 4 
patients. 
My questions to the authors are as follows. Have they 
had a similar trend of ischemia occurring not so much on 
the anastomotic site itself but extending especially into the 
intermediate bronchus? Do they have any experience with 
resection of bronchial stenosis? Finally, what do they 
think the reasons are for the higher prevalence of airway 
complications in SLT? 
Dr. Date. We have also seen several patients in whom 
stenotic hanges developed within the bronchus interme- 
dius. These have been ditficult o treat with conventional 
silicone-rubber stents. We have also seen malacia with 
intact mucosa. In these patients we have used a self- 
expandable metallic stent instead of a silicone-rubber stent 
and are pleased with the results. We have not used surgical 
resection to correct bronchial stenosis. 
As concerns the reason SLT is associated with more 
complications than BLT, it is possible that the collateral 
circulation in the parenchyma of the SET is not as good as 
that of the BLT. We have observed that, as a result of 
allograft dysfunction, the postoperative course of SLT for 
fibrosis or pulmonary hypertension is more complicated 
than that for BLT. BLT has theoretically a twofold risk of 
airway complication; however, if we calculate the airway 
complication per anastomosis, we find that SLT does have 
more complications than BLT. 
